Flot.bio x Philip Hemme

In our first episode recorded live in front of an audience, we’re with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering 🇸🇪 We talk about Flagship, including its EU activities. We also talk about company-building and Lovisa’s personal journey to be one of the leading Swedish leaders in biotech. ⭐️ ABOUT THE SPEAKER Lovisa is an icon in the EU biotech and pharma world, having been a CEO, co-founder, president, board chairman, and executive director in many emerging companies. Joining Flagship in 2020, she became the founding CEO of Alltrna, and co-founded/CEO of Apriori Bio, Metaphore Biotechnologies, and Prologue Medicines. Lovisa has received many accolades. A few include being listed on Inc. Magazine’s Female Founders 250 List in 2024, 2023 she featured in the PharmaVoice 100 list of life science industry leaders. 🔗 LINKS MENTIONED - Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial: https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx?os=vb&ref=app - Agnete Fredriksen, Nykode | Being one of the top 50 women in 🇪🇺 Bio | E07: https://flot.bio/episode/agnete-fredriksen-top-women-bio/ - BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024: https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-data-updates-across-mrna-and - Nouscom Raises €67.5 Million ($72 Million) In Oversubscribed Series C Financing Round: https://nouscom.com/2023/11/14/nouscom-raises-e67-5-million-72-million-in-oversubscribed-series-c-financing-round-2-2/ - Otello Stampacchia, Omega Funds 🇮🇹 | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:08] Flagship Pioneering and their EU biotech initiatives [00:06:18] Being creative in many biotech spheres [00:08:37] Why invest 50m in first seed Series A every time? [00:11:42] The Flagship Pioneering business model: invest early [00:15:57] VC-created vs founder-led biotechs [00:17:46] Raising one of the largest biotech funds [00:19:19] Flagship Pioneering’s biggest returns [00:22:36] AI & biotech [00:26:31] What does success mean to Flagship Pioneering [00:29:20] How to help biotech spinoffs grow and advice for women to be biotech leaders [00:34:03] How to move from computational to translation sciences & bring drugs to market faster [00:37:14] What can the EU learn from the US to create biotechs [00:40:36] How do you bridge the gap between biotech company creation in the US vs EU [00:43:07] Lessons for an early-stage biotech career [00:47:18] How to attract the best biotech talent [00:48:38] Moving to Boston [00:52:13] Quickfire [00:55:41] Thanks for listening

We’re in Budapest with Szabolcs Nagy, the founder of Turbine, one of the leading companies for AI in biotech in the world. We talked about AI in biotech at large. We also cover the differences between opening a platform versus doing proprietary drug development and building the company from central Europe. __ This episode is sponsored by Turbine, which can improve your drug development. Learn more at https://shorturl.at/w3Im6 __ ⭐️ ABOUT THE SPEAKER I’ve known Szabolcs since 2017 when he joined Bayer’s accelerator in Berlin. I found him incredibly inspiring back then and still to this day. Szabi began his serial entrepreneurship with the creation of a cybersecurity startup. Once that was acquired, he launched himself into the biotech scene with the founding of Turbine in 2015. 🔗 LINKS MENTIONED - Accenture's Investment in Turbine Enhances AI-Powered Cell Simulations for Biopharma R&D: https://www.biopharmatrend.com/post/806-accentures-investment-in-turbine-enhances-ai-powered-cell-simulations-for-biopharma-rd/ - After a tough year, Exscientia folds into Recursion to create an AI superpower: https://www.fiercebiotech.com/biotech/after-tough-year-exscientia-folds-recursion-create-ai-super-power 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/szabolcs-nagy-ai/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. [🎙️](https://x.com/FlotBio) ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:47] AI in Biotech [00:09:03] Open platform vs proprietary drug development [00:29:09] Pricing and value of AI technology in biotech [00:38:19] Working with the average biotech [00:42:42] History of Turbine and Szabolcs Nagy [00:53:36] Data-driven drug development [00:58:04] Quickfire

We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and Philly Cheesesteak vs Fish and Chips. — — — Thank you to today’s sponsor, Merck, who can support your antibody drug discovery. Learn more and claim a cool antibody pin here: https://bit.ly/3AhZFUA — — — ⭐️ ABOUT THE SPEAKER Adrian Rawcliffe has been in the biopharma industry for over 20 years and has worked in high positions for companies such as GSK. Adrian has been with Adaptimmune for almost 10 years, serving as CFO before becoming the CEO in 2019. I didn’t know him personally but have heard and seen great things about him. 🔗 LINKS MENTIONED - US FDA approves Adaptimmune's therapy for rare type of cancer: https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-adaptimmunes-gene-therapy-rare-cancer-2024-08-02/ - Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor: https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/271/adaptimmune-receives-u-s-fda-accelerated-approval-of - Galapagos selects Adaptimmune T-cell therapy for $665M biobucks collab: https://www.fiercebiotech.com/biotech/galapagos-selects-adaptimmune-t-cell-therapy-665m-biobucks-collab - FDA approves Iovance's Amtagvi as first T-cell therapy for a solid tumor: https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor - Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune: https://www.youtube.com/watch?app=desktop&v=AWIbHOJ1nUI&t=1121s - Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00319-2/abstract - Adaptimmune's CEO discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma: https://www.biotechtv.com/post/adaptimmune-august-2-2024 - Adrian’s LinkedIn profile: https://www.linkedin.com/in/adrawcliffe/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/adrian-rawcliffe-adaptimmune/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Introducing Adrian Rawcliffe [00:02:35] Commercial rollout of Tecelra, the first engineered cell therapy for solid tumors [00:07:35] The limits of TCR Cell Therapy [00:13:54] Market access in Europe [00:15:36] Peak sales projections [00:21:34] Next steps into 2025 [00:22:23] Rich History of Adaptimmune [00:28:47] GSK and transitioning to Biotech [00:35:54] BD & Partnering (or why not partner)[00:44:47] The Future of Cell Therapy: When will Allogeneic and In Vivo Therapies be on the Market? [00:48:43] Quick fire with Adrian Rawcliffe[00:50:20] Thanks for listening

We’re in Basel 🇨🇭 with the CEO of Nouscom, one of the top EU immuno-oncology biotechs in the cancer vaccine space, Marina Udier. We talked about cancer vaccines and Nouscom’s platform. We also discussed the importance of focus for success and her career. ⭐️ ABOUT THE SPEAKER Marina was recommended to me by one of her investors. She has an inspiring story, growing up in Croatia, going to the US, and making it all the way to be one of the 11% of female CEOs of biotechs in Europe in 2024. Now she is the CEO of Nouscom, but prior she was the Operating Principal at Versant Ventures, as well as holding top-level positions at Novartis Pharma, and McKinsey & Company. 🔗 LINKS MENTIONED - Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial - ****https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx?os=vb&ref=app - Agnete Fredriksen, Nykode | Being one of the top 50 women in 🇪🇺 bio | E07 - https://flot.bio/episode/agnete-fredriksen-top-women-bio/ - BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024 - https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-data-updates-across-mrna-and - Nouscom Raises €67.5 Million ($72 Million) In Oversubscribed Series C Financing Round - https://nouscom.com/2023/11/14/nouscom-raises-e67-5-million-72-million-in-oversubscribed-series-c-financing-round-2-2/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marina-udier-nouscom-cancer-vaccines/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. [🎙️](https://x.com/FlotBio) ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS - [00:00:00] Intro - [00:02:18] Cancer vaccines & Nouscom - [00:10:39] Bioinformatics algorithm - [00:15:16] Hype cycle in cancer vaccines - [00:26:04] $72M series C - [00:33:35] Managing a biotech board - [00:42:22] Personal story of Marina Udier - [00:48:17] Transition from Novartis - [00:54:00] Luck and timing in biotech - [00:56:10] Headwinds, Tailwinds - [00:58:13] Finding focus with a small team - [01:06:33] Gender diversity in biotech - [01:16:01] Quick fire - [01:18:37] Thanks for listening

We’re in Munich 🇩🇪 with the founder of one of the 15 most valuable European biotechs, Harpreet Singh. We talked about the field of PRAME receptors, TCR therapeutics and cell therapy at large. We also talked about the combination with mRNA therapeutics and his upbringing in a Sikh family in Germany. 🔗 LINKS MENTIONED Labiotech.eu | “Interview Harpreet Singh - Why Being in a New Field From the Start Can Pay Off in the Long Run”, Sep 2019: https://www.labiotech.eu/expert-advice/interview-singh-immatics/ Flot.bio | “Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14”, Mar 2024: https://www.youtube.com/watch?v=8bmGke4sRvE Edwin Moses | How to Build Large Biotech Platforms (like Ablynx) | E13: https://youtu.be/oMBcFC3PqyM?si=xTcZF27F0UFjyQhb ApexOnco | Immatics’ PRAME gift keeps on giving: https://www.oncologypipeline.com/apexonco/immatics-prame-gift-keeps-giving 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/harpreet-singh-immatics/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:00] PRAME & TCR space [00:12:43] Types of Cell Therapy [00:25:44] Commercialization [00:29:11] Valuations in Gene Therapy [00:33:17] Fundraising with Dievini and Struengmann [00:43:46] Sikh origin [00:48:31] Expanding to the US [00:53:59] PhD to CEO [00:59:21] Quickfire [01:03:01] Thanks for listening

We’re in Munich 🇩🇪 with a “true” biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis. We talked about building a champion ADC biotech, the super hot ADC sphere, and the difference between luck and success. 💎 ABOUT THE SPEAKER Dominik has had an incredible career, which he started from a young age. With the founding of Tubulis, he has won many start-up awards and in 2019 he was awarded MIT’s Innovators Under 35. As a life science investor, he has invested early in many European biotech companies. 🔗 LINKS MENTIONED - https://curie.bio/ - https://curie.bio - Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline - https://tubulis.com/news/tubulis-closes-upsized-e128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline/ - BioSpace - Next wave of ADCs - https://www.biospace.com/article/the-next-wave-of-adcs-could-treat-evasive-solid-tumors-/ - BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival - https://www.fiercebiotech.com/biotech/bms-axes-eisai-adc-pact-3-years-after-paying-650m-would-be-elahere-rival - Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - https://www.biospace.com/article/merck-s-adc-pact-with-daiichi-hits-regulatory-setback-with-fda-rejection/ - ADC Space is too crowded? - https://drive.google.com/file/d/1oA23bidvd2G-z2lnAkPLAMZgl1RXLtr9/view?usp=sharing - Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio ($1.8B cash) - https://ir.genmab.com/news-releases/news-release-details/genmab-broaden-and-strengthen-oncology-portfolio-acquisition - BIO-Europe Spring 2019: Newcomer Tubulis tackles ADC technology shortcomings - https://www.youtube.com/watch?v=wwr5KMypBHs - Top 20 Healthcare Specialist Investors - https://drive.google.com/file/d/1r4IwIKvuVUYQaqCZnpm4DtEYyy3LIT7h/view?usp=sharing 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/dominik-schumacher-tubulis/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:44] Entrepreneurial biotech family [00:08:46] Market validation [00:14:32] Why Munich [00:17:33] Founder-led biotechs [00:25:20] Balancing 3 kids [00:29:31] Tubulis & ADCs [00:38:25] ADC space is crowded [00:46:12] Deep Track Capital [00:48:17] Vision for Tubulis [00:52:59] ADC space is hot [00:58:03] Chinese biotech [01:02:53] Luck vs success

We’re in Boston 🇺🇸 with one of the top VCs, Otello Stampacchia of Omega Funds. We talked about the highest competitive tension in biopharma now that he has ever seen. We also talked about his career, especially the challenges and opportunities he had from moving to Boston over 15 years ago. 💎 ABOUT THE SPEAKER Otello is the founder and managing director of Omega Funds which he started in 2004. As an investment guru, he leads the investor relations and strategic initiatives. Previously Otello led the fund investment of one of the largest private equity asset managers in the world, AlpInvest Partners. He's also been involved in many European biotechs such as Lombard Odier Immunology Fund, Goldman Sachs, and Index Securities (now Index Ventures). 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/otello-stampacchia-omega-funds/ 💸 DONATE We welcome donations from individuals and businesses to support the show and more content creation: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:57] Competitive tension in biopharma [00:14:43] Cash in pharma [00:29:19] Personal background from Italy [00:41:10] Getting into venture capital [00:51:27] Decision to move to Boston [01:01:42] Thanks for listening

We’re in San Sebastián 🇪🇸 with one of the top VCs in Europe, Christina Takke from V-Bio Ventures. We talk about her path to get to the top and the benefits of gender diversity for both investing and European biotech as a whole. We also talk about her investment in Argenx when it was only three employees and the venture creation had dropped since 2022. 💎 ABOUT THE SPEAKER Christina co-founded V-Bio Ventures in 2015 and is now the Managing Partner. Before this, she was a leader in the European Venture Capital world with 15 years of experience. She has been a partner at Forbion Capital Partners where she led many successful investments in biopharma and pharma companies. 🔗 LINKS MENTIONED - Lean years for company creation in Europe? - BioVox, Sep 2023 - https://biovox.eu/lean-years-for-company-creation-in-europe/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/christina-takke-v-bio-ventures/ 💸 DONATE We welcome donations from individuals and businesses to support our more content creation: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:03] Top VC woman in biotech [00:08:36] European background [00:13:49] Investing in Argenx at the start [00:20:26] V-Bio story [00:25:09] Tech transfer [00:35:44] Company creation drop [00:42:39] Thanks for listening

We’re in San Sebastián 🇪🇸 with Naveed Siddiqi of one of Europe's largest biotech investors, Novo Holdings. We talked about how things really are in European biotech at the moment. We also talked about his upbringing as a second-generation immigrant in the UK and the importance of diversity. I’ve known him since he was a partner at Andera. He is a sharp investor, but also very friendly and open. 💎 ABOUT THE SPEAKER Naveed has been a part of Novo Holdings since 2019 and splits his time between London and Copenhagen. He has over 25 years of experience in life science venture investment as well as investment banking. Before joining Novo Holdings he was a partner at Andera Partners, a venture capital and growth equity firm with over 2 billion euros to focus on life science investment. 🔗 LINKS MENTIONED -Novo leads Q4 2023 as Top Investor - Oppenheimer: https://drive.google.com/file/d/1b-t2Ba-fnHdyJhIq4j-d7dSCk7Vj65bw/view?usp=sharing - Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group - https://amolytpharma.com/2023/01/06/amolyt-pharma-announces-138-million-series-c-financing-led-by-sofinnova-partners-and-co-led-by-intermediate-capital-group/ - AstraZeneca inks $800M buyout of French biotech to snag phase 3 rare disease drug - https://www.fiercebiotech.com/biotech/astrazeneca-inks-800m-buyout-snag-phase-3-rare-disease-drug - Novo-backed Amolyt Pharma snags $80M series B for endocrine pipeline - https://www.fiercebiotech.com/biotech/novo-backed-amolyt-pharma-snags-80m-series-b-for-endocrine-pipeline 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/naveed-siddiqi-novo-holdings/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:09] European biotech [00:18:06] Billion dollar exits [00:37:17] Diversity [00:45:04] Thanks for listening

We’re in Hannover 🇩🇪 with the founder and CEO of Cardior, Claudia Ulbrich We talked about Cardior’s recent €1B exit to Novo Nordisk. We also talk about miRNA and Cardiovascular, and why she earned the funny nickname “Frau Biotech”. 💎 ABOUT THE SPEAKER Claudia has been founding biotechs since the ’90s. She founded her first biotech company, LipoNova AG in 1998 and went on to co-found many more, including Cardior Pharmaceuticals. During her time she has launched and brought public a cancer vaccine company, helped see through a multi-million dollar deal of over €20M, and much more. 🔗 LINKS MENTIONED - Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167038 📜 TRANSCRIPT Read the full transcript here: 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X: https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:47] Novo Nordisk deal [00:10:19] Results from heart disease phase1 [00:19:55] MicroRNA [00:26:42] The history of Cardior [00:41:49] Working with Centerview [00:45:17] Frau Biotech [00:53:57] Thanks for listening

We’re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. 💎 ABOUT THE SPEAKER I’ve “known” Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market. 🔗 LINKS MENTIONED - Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f - Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success) 📜 TRANSCRIPT Read the full transcript here: 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:34] Welcome [00:01:46] Immunocore’s life-changing cancer drug [00:07:40] Commercializing Immunocore [00:13:46] Explaining the TCR technology [00:20:40] Targeting tumors with PRAME [00:23:26] Immunocore now and then [00:35:37] Why Bahija chose Immunocore [00:40:22] Top lessons from Bahija Jallal [00:45:48] How is risk appetite connected to innovation? [00:49:10] Diversity in biotech [01:00:59] Biological innovation [01:05:49] AI in protein engineering optimization [01:14:42] Thanks for listening

We’re in Brussels with Edwin Moses, the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. We talk about how he feels 5 years after the exit from Ablynx and his lessons. We also talk about the parallels between industrial biotech, AI bio and cell therapy, and how a chairman can help CEOs grow. 💎 ABOUT THE SPEAKER Edwin Moses is Chairman of Achilles Thx (cell therapy for solid tumors), Avantium (bioplastics) and LabGenius (AI biotech). He is the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. I interviewed him back in 2018 when he sold the company. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/edwin-moses-biotech-platforms/ 🔗 LINKS MENTIONED Sanofi to acquire Ablynx for €3.9 Billion - https://www.sanofi.com/en/media-room/press-releases/2018/2018-01-29-07-19-03-1313306 Edwin Moses on stage in 2018 - https://www.youtube.com/watch?v=nWkd99rxVhc&t=802s&pp=ygUVZWR3aW4gbW9zZXMgbGFiaW90ZWNo 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS

We’re in Copenhagen with Jens Nielsen, the CEO of BioInnovation Institute. We will talk about what works best to translate academic research in bio into innovation for humanity, especially how everything is connected. We also talk about how BII is solving some of the main challenges scientist entrepreneurs face and the drawbacks of Novo financing most of Denmark’s biotech ecosystem. 💎 ABOUT THE SPEAKER Jens Nielsen is one of the best in this space in Europe. Not only is he the CEO of BII, he’s also a professor of systems biology at Chalmers University of Technology in Sweden, and is the most cited researcher in the field of metabolic engineering as well as industrial biotechnology. He’s the founder of the International Metabolic Engineering Society and has also founded many biotechs. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/jens-nielsen-translation-of-life-science-research/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:29] Welcome [00:01:43] Translation of science [00:08:48] Being flexible is key [00:11:58] When to stop being flexible [00:19:34] Listen to your gut [00:22:38] The importance of network [00:28:05] Entrepreneurial mindset recipe [00:31:08] Role models [00:32:38] Interaction with industry [00:43:07] Results of BII [00:54:14] How to be cost-effective in helping startups [00:57:56] Novo Nordisk [01:11:07] Closing the lab [01:17:46] Thanks for listening

We’re in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and what’s missing in gene therapy. 💎 ABOUT THE SPEAKER Sander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the leading VC Forbion as well as Dezima. He is now building a new venture VectorY, again in gene therapy. I interviewed him in 2017 back at Labiotech so it’s great to catch up with him again. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/sander-van-deventer-gene-therapy/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:54] VectorY: Raising the largest Series A in 2023 in 🇪🇺 [00:05:01] What's coming for ALS [00:07:50] How Vectorized Antibodies work [00:17:57] New Vector (AAV) technologies [00:22:55] The pipeline of VectorY [00:27:22] Where VC money is moving to [00:32:29] The Netherlands as a biotech cluster [00:35:31] CRISPR approval and gene therapy reimbursement [00:48:15] Where Sander came from [00:56:14] How to have the energy to be a serial entrepreneur

In an online special, we’re interviewing Thomas Clozal, the co-founder and CEO of Owkin. We talk about scaling AI in biotech and how it feels to be the child of billionaire biotech parents. 💎 ABOUT THE SPEAKER Thomas founded Owkin in 2016 and I first met him in 2017. At that time, Owkin was still a baby and I wasn’t sure where it would go. Now it’s a unicorn following a $180M investment from Sanofi in 2021 and has over 300 employees. 🔗 LINKS MENTIONED - Exscientia Expands Biologics Design Capability with Automated Laboratory https://investors.exscientia.ai/press-releases/press-release-details/2022/Exscientia-Expands-Biologics-Design-Capability-with-Automated-Laboratory/default.aspx - Marc de Garidel, Abivax | How to make two billion 💶 exits (kind of smoothly) | E09 https://youtu.be/njZR8udGBTQ - How AI Can Tackle Cancer - Leader in Innovation (Fast Company) https://open.spotify.com/episode/2LQGtAaD7ALSsHslNZJ1mC?si=96a0ba9ddafd4fbc - Aviv Regev leads Genentech's next revolution with AI - https://endpts.com/aviv-regev-leads-genentechs-next-revolution-with-ai/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/thomas-clozel-ai-biotech/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:26] You need a good pipeline [00:09:24] How Owkin is scaling AI in biotech [00:16:46] Augmenting AI in biotech [00:23:05] How AI can work for small/medium biotech companies [00:27:18] Always looking for more data [00:33:58] Anonymization of data and federated learning [00:42:18] Becoming a biotech company [00:47:29] Small molecules [00:49:10] Limitations [00:51:51] Growing up with billionaire biotech parents [00:56:37] Becoming unfocused and having fun [01:09:02] Getting the best investors [01:18:51] Thanks for listening

Today, I’m in Paris (🇫🇷) to chat with Marc de Garidel, the new CEO of Abivax. We talk about the challenges behind the exits and why Abivax could be a third big success. 💎 ABOUT THE SPEAKER Marc is a biopharma veteran with an impressive track record. He has made two billion-dollar exits, was CEO of Ipsen, and has recently made the biggest French IPO ever with Abivax. He has also raised $60M series B for Massachusetts-based Corvidia Therapeutics before being acquired for $2.1B by Novo Nordisk. He also was the CEO of CinCor Pharma which sold for $1.8B to AstraZeneca in 2023. I’ve never met Marc but I heard many great things about him. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marc-de-garidel-abivax-exit/ 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmH LinkedIn: https://www.linkedin.com/company/flot-bio/ X (Twitter): https://x.com/FlotBio 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Wanna reach 10,000+ biotech leaders at companies like BioNTech, Immunocore or Genmab? Feel free to message Nick (nick@flot.bio) to learn more. 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:32] Behind the scene of the 2 billion-dollar exits [00:20:48] Lessons on compliance analysis [00:24:09] What to do when the market is against you [00:36:08] Abivax: Phase II compared to standard of care [00:42:51] IBD and the microbiome [00:51:20] Why is 70% of the market in the US? [00:59:07] The best way to sell a company is to make a great product [01:03:48] Find people who inspire you [01:10:45] Thanks for listening 🙏

Today we're in Munich at BIO-Europe to chat with one of the best commentators in European biotech, Mike Ward. We talk about the best and the worst of the European biotech industry since the 80s. 💎 ABOUT THE SPEAKER Mike has been in biotech content since the birth of the industry in the 80s. He has worked at BioCentury, Informa/Scrip and now Clarivate. I’ve known Mike for many years and I like how clearly he sees things while being no-bullshit and fun. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/y428h2wr 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): [https://x.com/FlotBio 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:32] The best and worst of biotech [00:11:08] The beginnings of the EU biotech scene [00:21:38] It's all in cycles and echos [00:28:14] Biotech of today [00:45:12] Can biotechs make money? [00:56:31] Funding big vs small [01:16:15] The EU biotech world is very small [01:21:45] The changing media landscape [01:38:35] The rockstar of biotech [01:43:18] Thanks for listening

We’re live from Oslo 🇳🇴 to catch up with Agnete Fredriksen, co-founder and CBO of Nykode (ex-Vaccibody). In this episode, we chat about being one of the leading women in bio in Europe, the Nordics, and immunotherapies. 💎 ABOUT THE SPEAKER Agnete founded the immunotherapy company Nykode in 2006 which is now worth around $500M. For her PhD she designed and developed the first Vaccibody vaccine molecules, improving the outlook for cancer patients. I’ve known Agnete for many years and I like her sharpness while having this Scandinavian humility. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/yk364wes 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter) https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. These might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:52] Welcome [00:01:36] Women in biotech [00:25:35] Gender equality on the board [00:42:10] Raising $45 million [00:47:47] How the science works [01:01:20] Explaining the clinical results [01:07:19] The immunotherapy field [01:17:02] Biotech in Oslo [01:21:08] Thanks for listening

Biotech great Rodger Novak, Co-Founder and Chairman of CRISPR Tx joins us on the show. In this episode, we chat about bringing the first CRISPR drug to the market and why he thinks everything is wrong in bio in Europe besides science. Rodgers’ is a name everyone should know, having made it big in the global biotech scene. I first interviewed him back in 2016 at Labiotech. It’s a treat to be able to sit down with him again. 💎 ABOUT THE SPEAKER A serial entrepreneur, Rodger Novak has made it big through his many successful enterprises in the pharma and biotech scene. As co-founder of one of the hottest and best-known biotechs in the world, CRISPR Tx, he has been an instrumental player in bringing cutting-edge gene therapy to the world. Trained with a medical degree, he has also provided key contributions in the fields of anti-infectives, genetics and personalized medicine. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/9kucsnzt 🔗 LINKS MENTIONED: - Rodger at Hello Tomorrow 2022 - https://youtu.be/OWMRlLzJ5l8 - Rodger at Labiotech Refresh in 2019 - https://youtu.be/kp6m6BDckDk?si=RhjDeDi-n0crXMra - Rodger at Labiotech Refresh in 2016 - https://youtu.be/XFK-B1xJzGc?si=TG7ut5f-aGEgpLwg - Rodger on the Between Biotech Waves podcast - https://open.spotify.com/episode/1PFWLgJ80QmZwdN9Rmy6a7?si=0QLdSEJTSIe_et0vDarYmQ 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. These might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:38] Welcome [00:01:45] Bringing CRISPR to the market [00:17:33] Experience in biotech isn't everything [00:21:35] How important is CRISPR? [00:27:07] How to become best in class [00:33:40] The secret recipe for founding a successful company [00:37:28] Everything is wrong in biotech in Europe besides science [00:46:44] What can a young European founder do to bridge the US gap for biotech [00:57:01] The European attitude can get in the way of entrepreneurship [01:06:20] Follow Rodger Novak [01:09:23] Thanks for listening and follow Flot.bio

We’re back live and in Paris 🇫🇷 with our next guest, Johannes Fruehauf. We talk about reinventing the co-working labs for biotech startups, the difficulties of doing business in Europe, profitability in biotech, and much more (see timestamps below). 💎 ABOUT THE SPEAKER Johannes is the President, CEO, and founder of BioLabs, the biggest “incubator”, or as they like to call it “co-working laboratory”, platform for biotech startups in the world. Today they have over 14 locations, including 3 in Europe (2 in Paris and 1 in Heidelberg). He is also the founder of LabCentral and a general partner at Mission BioCapital.  📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/mt9dva8u 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:39] Welcome to this new episode [00:02:19] How & why reinvent biotech incubators [00:14:14] The competitors [00:17:41] Entrepreneurship in Europe [00:22:11] The Challenges of doing business in Europe [00:29:37] People make it happen [00:36:51] BioLabs in Asia and Japan [00:41:46] Is a higher risk tolerance a good thing for everyone? [00:48:22] Money: being profitable in life sciences and not raising money if you don't have to. [00:59:15] Synergies between real estate and investing [01:14:01] Should you get a business coach? [01:25:52] Thanks for listening